Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.

Abstract: A closed loop-type hemostatic device having built-in inner pincers which integrates holding type pincers with a device for fitting a hemostatic clip, so as to: primarily, find and temporarily perform hemostasis on a bleeding portion by using holding type pincers after confirming that the bleeding portion exists; secondarily, move a clip pressing part and a clip pressing part and enclose the bleeding portion; and then move only the clip pressing part and clip a closed loop-type hemostatic clip onto the bleeding portion so as to perform hemostasis. The amount of bleeding can be reduced by temporary hemostasis on a bleeding portion, and a hemostatic clip can be precisely clipped on the bleeding portion, thereby improving hemostatic performance. Also, because hemostasis can be selectively performed only around a damaged blood vessel wall, therefore, the physiological benefit of being able to maintain partial blood flow may be provided.

Abstract: The present invention provides a marker which can be used as an indicator for efficacy prediction of an mTOR related anticancer agent or prognostic prediction, and a novel anticancer agent. The present invention provides a method for efficacy evaluation of a cancer drug, and, specifically, a prediction method for the efficacy of an mTOR-related cancer drug by detecting NRF2 abnormality. In addition, the present invention provides a prognostic prediction method for cancer, and, specifically, a prediction method for the prognosis of cancer by detecting NRF2 abnormality. Furthermore, the present invention provides a novel anticancer agent that targets NRF2.

Abstract: The invention provides a method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells.

Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.

Abstract: An image analysis method for generating data indicating a tumorigenic state of an image of a tissue or a cell. The image analysis method is an image analysis method for analyzing an image of a tissue or a cell using a deep learning algorithm of a neural network structure, analysis data are generated from the analysis target image including a tissue or cell to be analyzed, the analysis data are input to the deep learning algorithm, and data indicating the tumorigenic state of tissues or cells in the analysis target image are generated by the depth learning algorithm.

Abstract: The present invention relates to a fluorescent image system capable of generating white light by mixing three monochromatic lights, i.e. red, green and blue monochromatic lights, having a narrow band wavelength, instead of white light of constant wavelength; providing a fluorescent image-use light source that generates a mixed light by adding a fluorescent excitation light source suitable for fluorescent substances; and photographing a general image and fluorescent image simultaneously with the light sources.

Abstract: The present invention provides a kit or device for the detection of malignant brain tumor, and a method for detecting malignant brain tumor. The present invention relates to a kit or device for the detection of malignant brain tumor, comprising nucleic acid(s) capable of specifically binding to predetermined miRNA(s) in a sample of a subject, and a method for detecting malignant brain tumor, comprising measuring the miRNA(s) in vitro.

Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.

Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.

Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.

Abstract: The present invention provides a method for producing hepatic stem/progenitor cells from mammal hepatocytes, comprising bringing a TGF?-receptor inhibitor, and optionally a GSK3 inhibitor and/or a ROCK inhibitor into contact with the hepatocytes in vitro.

Abstract: The present invention relates to a labeling composition for a cancer lesion, having a complex in which a pigment for straining living tissues, a radioactive isotope, or a combination thereof binds to macro aggregated albumin (MAA). A method for providing information regarding a cancer lesion site using the labeling composition for a cancer lesion. A labeling kit for a cancer lesion having the labeling composition for a cancer lesion; and a complex in which a pigment for straining living tissues binds to MAA included in the labeling composition for a cancer lesion. The labeling composition for a cancer lesion according to the present invention binds to a cancer lesion to detect a site, size, and the like of the cancer lesion in real time, thereby improving the success rate of a surgical operation for the cancer lesion and also preventing excessive loss of normal tissues.

Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.

Abstract: Provided is a colorectal cancer inspection method by which the presence of early colorectal cancer at any one of stages from 0 to 2 can be accurately determined. The colorectal cancer inspection method includes: measuring the amounts of at least lactic acid, pyruvic acid, and glycolic acid among a plurality of kinds of in vivo metabolites contained in a biological sample collected from a test subject, based on data obtained by performing a chromatograph-MS/MS analysis on the biological sample; and determining the presence of colorectal cancer at any one of stages from 0 to 2, based on a measurement value of at least one of the lactic acid, the pyruvic acid, and the glycolic acid.

Abstract: A skull implant medication injection port comprises: a mounted portion placed on an upper section of a port insertion hole in a patient's cranium and a medication inlet on a top surface; a medication injection diaphragm that seals the medication inlet of the mounted portion where a needle for injecting a medication is inserted; a medication storage portion coupled with a bottom of the mounted portion stores the medication injected through the medication injection diaphragm; a medication discharge pipe connected to the medication storage portion discharges the medication stored in the medication storage portion; and a rib formed on a perimeter between the mounted portion and the medication storage portion that has a diameter larger than an inner diameter of the port insertion hole. A height of the mounted portion is generally about 4 to 7 mm, and a height of the medication storage portion is generally about 2 to 4.2 mm.

Abstract: The present invention relates to a pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients. Specifically, the combinative treatment with gossypol and phenformin was verified to have a significantly higher anticancer activity than a single treatment with gossypol and phenformin alone. Therefore, the pharmaceutical composition of the present invention containing gossypol and phenformin having a synergetic anticancer activity can be favorably used for cancer treatment.

Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.